{"resourceType": "Group", "meta": {"versionId": "5", "lastUpdated": "2025-03-15T20:58:52.894Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"]}, "title": "ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria", "status": "active", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-11-16. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340#json."}], "url": "https://fevir.net/resources/Group/279340", "id": "279340", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/279340", "assigner": {"display": "Computable Publishing LLC"}}], "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "description": "Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria\na. T1DM-specific criteria\n..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have been on the following daily insulin therapy for at least 1 year\n...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or\n...2) continuous subcutaneous insulin infusion (CSII)\n..iii. are between 18 and 64 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening\nb. T2DM-specific criteria\n..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\n..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\n..iii. are between 20 and 70 years old at the time of informed consent\n..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening", "membership": "conceptual", "combinationMethod": "any-of", "characteristic": [{"description": "T1DM-specific criteria\ni. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria\nii. have been on the following daily insulin therapy for at least 1 year\n..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)\niii. are between 18 and 64 years old at the time of informed consent\niv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening", "code": {"text": "Defined by Reference"}, "valueReference": {"reference": "Group/279347", "type": "Group", "display": "CohortDefinition: T1DM-specific criteria"}, "exclude": false}, {"description": "T2DM-specific criteria\ni. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening", "code": {"text": "Defined by Reference"}, "valueReference": {"reference": "Group/279346", "type": "Group", "display": "CohortDefinition: T2DM-specific criteria"}, "exclude": false}], "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}}